NBTXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as NNBXF
Nanobiotix S.A.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 31, 2026
$21.08−0.22 (-1.03%)
Close on Oct 19, 2026
Nanobiotix S.A. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| Services | €22.68M | -€17.53M | €29.75M | €0 | €5.00K | €50.00K | €40.00K | €109.00K | 69.6% | -229.4% |
| Research and Development | €21.80M | – | – | – | – | – | – | – | 66.9% | – |
| Other sales | €6.96M | €5.92M | €308.00K | €0 | €5.00K | €0 | €28.00K | €7.00K | 21.4% | +17.5% |
| Other Services | €900.00K | – | – | – | – | – | – | – | 2.8% | – |
By region
From the segment and revenue-disaggregation notes of Nanobiotix's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.